Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 26 of the 48 sources its claims cite were checked for support.
Abstract
BACKGROUND: Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma. We investigated cilta-cel in earlier treatment lines in patients with lenalidomide-refractory disease. METHODS: In this phase 3, randomized, open-label trial, we assigned patients with lenalidomide-refractory multiple myeloma to receive cilta-cel or the physician's choice of effective standard care. All the patients had received one to three previous lines of treatment. The primary outcome was progression-free survival. RESULTS: A total of 419 patients underwent randomization (208 to receive cilta-cel and 211 to receive standard care). At a median follow-up of 15.9 months (range, 0.1 to 27.3), the median progression-free survival was not reached in the cilta-cel group and was 11.8 months in the standard-care group (hazard ratio, 0.26; 95% confidence interval [CI], 0.18 to 0.38; P<0.001). Progression-free survival at 12 months was 75.9% (95% CI, 69.4 to 81.1) in the cilta-cel group and 48.6% (95% CI, 41.5 to 55.3) in the standard-care group. More patients in the cilta-cel group than in the standard-care group had an overall response (84.6% vs. 67.3%), a complete response or better (73.1% vs. 21.8%), and an absence of minimal residual disease (60.6% vs. 15.6%). Death from any cause was reported in 39 patients and 46 patients, respectively (hazard ratio, 0.78; 95% CI, 0.5 to 1.2). Most patients reported grade 3 or 4 adverse events during treatment. Among the 176 patients who received cilta-cel in the as-treated population, 134 (76.1%) had cytokine release syndrome (grade 3 or 4, 1.1%; no grade 5), 8 (4.5%) had immune effector cell-associated neurotoxicity syndrome (all grade 1 or 2), 1 had movement and neurocognitive symptoms (grade 1), 16 (9.1%) had cranial nerve palsy (grade 2, 8.0%; grade 3, 1.1%), and 5 (2.8%) had CAR-T-related peripheral neuropathy (grade 1 or 2, 2.3%; grade 3, 0.6%). CONCLUSIONS: A single cilta-cel infusion resulted in a lower risk of disease progression or death than standard care in lenalidomide-refractory patients with multiple myeloma who had received one to three previous therapies. (Funded by Janssen and Legend Biotech; CARTITUDE-4 ClinicalTrials.gov number, NCT04181827.).
Overview
CoChat Summary
TL;DR
In CARTITUDE-4, a single cilta-cel infusion significantly improved progression-free survival versus physician’s choice standard care in lenalidomide-refractory multiple myeloma after one to three prior lines. Cilta-cel also produced higher response and MRD-negativity rates, with mostly manageable CAR-T-specific adverse events.
Key findings
- At a median follow-up of 15.9 months, median progression-free survival was not reached with cilta-cel versus 11.8 months with standard care (HR, 0.26; 95% CI, 0.18 to 0.38; P<0.001); 12-month progression-free survival was 75.9% vs. 48.6%.
- Cilta-cel produced higher overall response (84.6% vs. 67.3%), complete response or better (73.1% vs. 21.8%), and MRD negativity (60.6% vs. 15.6%).
- Overall survival was immature: death from any cause occurred in 39 cilta-cel patients and 46 standard-care patients (HR, 0.78; 95% CI, 0.5 to 1.2; P=0.26); 12-month survival was 84.1% vs. 83.6%.
- Grade 3 or 4 adverse events occurred in 96.6% vs. 94.2%; among 176 as-treated cilta-cel patients, cytokine release syndrome occurred in 76.1% (grade 3 or 4, 1.1%; no grade 5), ICANS in 4.5% (all grade 1 or 2), cranial nerve palsy in 9.1%, and CAR-T-related peripheral neuropathy in 2.8%.
Methods
- Phase 3, randomized, open-label trial at 81 sites in the United States, Europe, Asia, and Australia; 419 patients with lenalidomide-refractory multiple myeloma after one to three prior lines, ECOG performance-status score ≤1, and no prior CAR-T or BCMA-targeted therapy were assigned 1:1 to cilta-cel (208) or standard care (211; PVd or DPd).
- Cilta-cel patients received apheresis, bridging therapy, lymphodepletion, and a single cilta-cel infusion (target dose, 0.75×10^6 CAR+ viable T cells/kg); standard-care patients received DPd or PVd until progression, with no protocol-permitted crossover.
- Primary outcome was progression-free survival; efficacy was analyzed in the intention-to-treat population with Kaplan-Meier estimates, a stratified weighted log-rank test, and stratified Cox regression; adverse events were evaluated in the safety population and CAR-T-specific events in the as-treated population.
Limitations
- Stated: two highly efficacious triplet regimens—daratumumab, carfilzomib, and dexamethasone and isatuximab, carfilzomib, and dexamethasone—were not approved at trial initiation and could not be included as standard-care options.
- Stated: early progression or death during weeks 0 to 8 was higher in the cilta-cel group and all occurred before cilta-cel infusion; this may have been due to lower bridging doses of DPd/PVd, and the benefit did not become apparent until 3 months. Overall survival data were immature.
- Evident: the trial was open-label, the sponsor was involved in data collection, analysis, and interpretation, and median follow-up was 15.9 months, limiting assessment of overall survival; crossover from standard care to cilta-cel was not permitted.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Valid · 2 Not valid · 4 Not checked · 86 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In the phase 1b-2 CARTITUDE-1 trial involving patients who had received at least three lines of therapy, the median progressionfree survival was 34.9 months. 10-12”
What the sources say
- Not checked — no full text of the sourcecites [10] 10. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398: 314-24. source
- Disputedcites [11] 11. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023; 41: 1265-74. sourceExperimental — accuracy not yet measured
The Results > Efficacy section states that median progression-free survival was not reached at a median follow-up of 27.7 months, contrary to the claimed 34.9 months. The Methods > Study Design and Treatment section confirms that CARTITUDE-1 was a phase Ib/II trial, but its eligibility criteria also allowed some patients with fewer than three prior lines of therapy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [12] 12. Lin Y, Martin TG, Usmani SZ, et al. CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/ refractory multiple myeloma. J Clin Oncol 2023; 41: Suppl: 8009. abstract. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“High treatment attrition - only 13 to 35% of patients receive four or more lines of therapy - also highlights the need to use effective therapies early. 9”
What the sources say
- Supportedcites [9] 9. Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer 2020; 20: 1087. source
Table 4 (Results, Attrition by LOT) shows that 2,971 of 22,062 non-transplant patients (13.5%) and 954 of 2,763 transplant patients (34.5%) received a fourth line of therapy. The Conclusion links high attrition to the need for effective treatment early. These percentages concern patients in the study who received at least one line of therapy, not all patients diagnosed with multiple myeloma. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The frequency of lenalidomide resistance early in the treatment journey is increasing, 1,8”
What the sources say
- Supportedcites [1] 1. van de Donk NWCJ. Sequencing multiple myeloma therapies with and after antibody therapies. Hematology Am Soc Hematol Educ Program 2020; 2020: 248-58. source
In the Introduction sections “Changes in frontline treatment” and “Refractory to lenalidomide,” the paper says that increasing frontline use of lenalidomide is leading to an increasing fraction of patients with lenalidomide-refractory disease at first relapse. This supports the claim about resistance occurring more frequently early in the treatment journey. (LLM, conf=0.94)
- Supportedcites [8] 8. de Arriba de la Fuente F, Montes Gaisán C, de la Rubia Comos J. How to manage patients with lenalidomide-refractory multiple myeloma. Cancers (Basel) 2022; 15: 155. source
The Introduction states that, with extensive use of frontline lenalidomide-based therapies, lenalidomide refractoriness early in the disease course is increasingly common. This directly supports the citing sentence’s paraphrase. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The incidence of movement and neurocognitive adverse events was also lower in CARTITUDE-4 (0.6%) than in CARTITUDE-1 (6.0%)”
What the sources say
- Not checked — no full text of the sourcecites [10] 10. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398: 314-24. source
- Partly supportedcites [11] 11. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023; 41: 1265-74. sourceExperimental — accuracy not yet measured
The Results section identifies parkinsonism as previously termed movement and neurocognitive adverse events, and the Discussion reports a 6% incidence in CARTITUDE-1. The paper does not give a CARTITUDE-4 incidence of 0.6%; it instead reports less than 0.5% across other cilta-cel studies without identifying CARTITUDE-4. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“which suggests that cilta-cel may have a better side-effect profile when used earlier in treatment. 10,11”
What the sources say
- Not checked — no full text of the sourcecites [10] 10. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398: 314-24. source
- Partly supportedcites [11] 11. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023; 41: 1265-74. sourceExperimental — accuracy not yet measured
The Discussion (page not available) says earlier use of cilta-cel may improve long-term outcomes and notes that prior treatments in this heavily pretreated group are associated with an increased risk of secondary primary malignancies. It does not say that cilta-cel itself would have fewer side effects if used earlier, so the specific safety comparison remains unsupported. (LLM, conf=0.78)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
43 more claims
Create a free account to see all 109 claims and every source verdict.
- Probably not a substantial claim. 35
- It may state two separate claims as one. 30
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The proportion of patients over age 75 years or with an Eastern Cooperative Oncology Group performance status score of 2 were also small but consistent with results reported in studies of similar populations;5,26,28,33 a progression-free survival benefit was still observed with Tec-Dara in these subgroups.”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients in the cilta-cel arm of CARTITUDE-4 who had increased tumor burden after bridging therapy or lymphodepletion were assessed as having PD and could receive cilta-cel as subsequent therapy at the investigator ' s discretion 14 ; in KarMMa-3, these patients were permitted to remain on study.”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably in KarMMa-3, 54% (207/386) of patients were enrolled in the United States compared with 15% (64/419) in CARTITUDE-4. 14”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ciltacabtagene autoleucel, a BCMA autologous CAR-T therapy, has significantly improved progression-free and overall survival versus DPd/PVd, with an improving adverse event profile from late to earlier lines of treatment.5,25”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Both ide-cel and cilta-cel have subsequently shown superiority over standard relapsed myeloma regimens in randomized trials conducted earlier in the disease course (Table 9).159,160”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [160]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“During treatment, infections occurred in 129 patients (62.0%) in the cilta-cel group and in 148 (71.2%) in the standard-care group; of these infections, 26.9% and 24.5%, respectively, were of grade 3 or 4.”
Reported 26.9 · recomputed 43.410853
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Immune effector cell-associated neuro- toxicity syndrome and associated symptoms | 8/176 (4.5) | 1/176 (0.1)”
Reported 0.1 · recomputed 0.568182
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“MRD negativity at any time during the trial occurred in 60.6% of the patients in the cilta-cel group and in 15.6% of those in the standard-care group, for a risk ratio of 2.2”
Reported 2.2 · recomputed 3.884615
Citations
Cites
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citationDaratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationIde-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213614 · Cited by 781
Self-citationMartin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00842 · Cited by 663
Self-citationDimopoulos, M., Quach, H., Mateos, M.-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Yang, H., Klippel, Z., Zahlten-Kumeli, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30734-0 · Cited by 430
Self-citationMoreau, P., Dimopoulos, M.-A., Mikhael, J., Yong, K., Capra, M., Facon, T., Hajek, R., Špička, I., Baker, R., Kim, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00592-4 · Cited by 392
Self-citationRichardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30152-4 · Cited by 386
Self-citation
Cited by
Items 101–200 of 814
Farahnak, K., Bai, Y. Z., Yokoyama, Y., Morkan, D. B., Liu, Z., Amrute, J., Falcon, A. D. F., Terada, Y., Liao, F., Li, W., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci170118 · Cited by 23
IgG replacement in multiple myeloma
Wonnaparhown, A. M., Hilal, T., Squire, J. D., Freeman, C. M., & Fonseca, R. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01107-6 · Cited by 28
“The phase 3 CARTITUDE-4 trial comparing cilta-cel versus standard of care therapy after 1 – 3 prior lines of therapy also showed decreased disease progression and death in refractory MM patients [25].”
Methodvan de Donk, N. W. C. J., Rasche, L., Sidana, S., Zweegman, S., & Garfall, A. L. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0124 · Cited by 29
Self-citationSecond Primary Cancer After Chimeric Antigen Receptor–T-Cell Therapy: A Review
Patel, S. A., Spiegel, J. Y., & Dahiya, S. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.5412 · Cited by 28
Mina, R., Mylin, A. K., Yokoyama, H., Magen, H., Alsdorf, W. H., Minnema, M. C., Shune, L. O., Isufi, I., Harrison, S. J., Shah, U. A., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00320-x · Cited by 27
Self-citationDong, S., Li, X., Huang, Q., Li, Y., Li, J., Zhu, X., Xue, C., Chen, R., Zeng, Y., Wu, J., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101215 · Cited by 29
Avigan, Z. M., Catlett, J. L., Bodnar, S., Pan, D., Aleman, A., Sheng, T., Moshier, E. L., Rossi, A., Richard, S., Kaur, G., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1587 · Cited by 33
“Chimeric antigen receptor T cells (CAR-T) targeting B-cell maturation antigen (BCMA) have transformed the therapeutic landscape of multiple myeloma, with durable responses in heavily pretreated patients and two commercial products approved as early as first relapse (1, 2).”
Current Novel Targeted Therapeutic Strategies in Multiple Myeloma
Lin, C. H.-T., Tariq, M. J., Ullah, F., Sannareddy, A., Khalid, F., Abbas, H., Bader, A., Samaras, C. J., Valent, J. N., Khouri, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116192 · Cited by 31
Soluble B‐cell maturation antigen in multiple myeloma
Costa, B. A., Ortiz, R. J., Lesokhin, A. M., & Richter, J. R. (2024) · American Journal of Hematology · doi:10.1002/ajh.27225 · Cited by 28
Blanquart, E., Ekren, R., Rigaud, B., Joubert, M.-V., Baylot, V., Daunes, H., Cuisinier, M., Villard, M., Carrié, N., Mazzotti, C., et al. (2024) · Blood · doi:10.1182/blood.2023023529 · Cited by 29
Gay, F., Marchetti, E., & Bertuglia, G. (2025) · Hematological Oncology · doi:10.1002/hon.70067 · Cited by 37
“These products have also shown superior outcomes compared to standards of care, in early lines of therapy in the randomized CARTITUDE‐4 [80] and KarMMa‐3 [81] trials.”
Long‐term survivorship care after CAR‐T cell therapy
Puckrin, R., Jamani, K., & Jimenez-Zepeda, V. H. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14100 · Cited by 29
“14 A movement and neurocognitive disorder with features of Parkinsonism was reported in 5% of patients treated with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1.”
BackgroundBCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them
Rees, M. J., & Kumar, S. K. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2284088 · Cited by 23
“…and infectious risk. like BcMA-directed BsAb, hypogammaglobulinemia affects approximately 75–90% of cAR t recipients [51,52]. while infectious complications are common, all grades 50–60% and grade ≥ 3–25%, this is not significantly higher than other extensively treated MM patients [47,51,52].”
BackgroundMethodResultInfluentialEstimation of eligibility for and response to CAR-T therapy in the United States
Haslam, A., Høeg, T. B., & Prasad, V. K. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011184 · Cited by 26
Sales, C., Anderson, M. A., Kuznetsova, V., Rosenfeld, H., Malpas, C. B., Roos, I., Dickinson, M. J., Harrison, S. J., & Kalinčík, T. (2023) · European Journal of Neurology · doi:10.1111/ene.16174 · Cited by 23
“%) cases of craniopathies [17, 18].”
Self-citationAilawadhi, S., Shune, L. O., Wong, S. W. K., Lin, Y., Patel, K. K., & Jagannath, S. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.01.014 · Cited by 25
Therapeutic progress in relapsed/refractory multiple myeloma
Chen, Q., Zhang, M., Zheng, S., Tong, Y., & Tan, Y. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05730-y · Cited by 31
Goldsmith, S. R., Shouse, G., Wong, F. L., Bosworth, A., Iukuridze, A., Chen, S., Rhee, J., Mei, M. G., Htut, M., Janakiram, M., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.06.008 · Cited by 29
Rees, M. J., Mammadzadeh, A., Bolarinwa, A. B., Elhaj, M., Bohra, A., Bansal, R., Ailawadhi, S., Parrondo, R. D., Chhabra, S., Khot, A. S., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01081-z · Cited by 27
“…more triple-class and penta-class refractory disease in the ide-cel arm, these results are consistent with; KarMMa-3 where ide-cel had median PFS of 12-months in patients with 2 – 4 previous LOTs, and CARTITUDE-4 where cilta-cel had 12-month PFS of 76% in lenalidomide refractory patients [16, 17].”
ResultCardiovascular toxicities associated with novel cellular immune therapies
Munir, M., Sayed, A., Addison, D., & Epperla, N. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013849 · Cited by 28
Emerging T-cell lymphomas after CAR T-cell therapy
Braun, T., Kuschel, F., Reiche, K., Merz, M., & Herling, M. (2025) · Leukemia · doi:10.1038/s41375-025-02574-x · Cited by 27
“Chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment landscape for relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) and multiple myeloma (MM), delivering unprecedented response rates even in heavily pre-treated patients [1, 2].”
Atanackovic, D., Luetkens, T., Schneider, D., Hu, P., Wang, X., Shetty, A. C., Tallon, L. J., Patel, I., Singh, R., Gebru, E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60980-2 · Cited by 29
“We have amended our manuscript accordingly.”
Rade, M., Fandrei, D., Kreuz, M., Seiffert, S., Grahnert, A., Friedrich, M., Wiemers, T. C., Born, P., Fischer, L., Weidner, H., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.10.014 · Cited by 39
Self-citationTeclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
Touzeau, C., Mina, R., Quach, H., Hungria, V., Bhutani, D., Chen, W., Kumar, S. S., Chaulagain, C. P., Dimopoulos, M. A., Bahlis, N. J., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2603870 · Cited by 39
Self-citationManaging side effects: guidance for use of immunotherapies in multiple myeloma
Liang, E. C., & Sidana, S. (2023) · Hematology · doi:10.1182/hematology.2023000435 · Cited by 25
Self-citationAnswering the “Doctor, can CAR-T therapy cause cancer?” question in clinic
Banerjee, R. K., Poh, C., Hirayama, A. V. V., Gauthier, J., Cassaday, R. D., Shadman, M. S., Cowan, A. J., Till, B. G., Green, D. J., Kiem, H., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012336 · Cited by 23
“6-10 Given the “ one-and-done ” nature of CAR T infusions coupled with their potential for rapid and durable remissions, several trials have also shown that CAR T outperforms standard therapies in terms of meaningful improvements in quality of life.”
BackgroundAntigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity
Sun, Y., Yang, X., Yang, S., Lyu, Y., Zhang, B., Liu, K., Li, N., Cui, J.-C., Huang, G.-X., Liu, C.-L., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01686-z · Cited by 25
“Thanks to encouraging clinical results in treating RRMM, 23,24,27 – 30 cilta-cel is gaining momentum in regulatory approval worldwide.”
BackgroundEfficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells
Volta, L. G., Myburgh, R., Pellegrino, C. E., Koch, C., Maurer, M., Manfredi, F., Hofstetter, M., Kaiser, A., Schneiter, F., Müller, J., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02409-1 · Cited by 20
“Speci fi cally, CAR T-cells directed against CD19 B-cell and BCMA plasma cell lineage antigens have led to improved clinical outcomes in patients suffering from advanced B-lymphoid and plasma cell malignancies [3 – 5].”
Evolving strategies for addressing CAR T-cell toxicities
Rankin, A. W., Duncan, B. B., Allen, C., Silbert, S. K., & Shah, N. N. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10227-1 · Cited by 23
A Review of CAR T Cells and Adoptive T-Cell Therapies in Lymphoid and Solid Organ Malignancies
Parums, D. V. (2025) · Medical Science Monitor · doi:10.12659/msm.948125 · Cited by 34
“…CAR T-cell therapy with Idecabtagene vicleucel (Abecma) and ciltacabtagene au-toleucel (cita-cel or Carvykti) compared standard-of-care treatments for patients with previously treated multiple-myeloma, and prior treatment showed superior progression-free survival with CAR T-cell therapy [19-21].”
Oliver‐Caldés, A., Español‐Rego, M., Zabaleta, A., González‐Calle, V., Velázquez, S. N., Inogés, S., de Cerio, A. L.-D., Cabañas, V., López‐Muñoz, N., Rodríguez‐Otero, P., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3759 · Cited by 21
Self-citationNeurotoxic complications of chimeric antigen receptor (CAR) T-cell therapy
Vonberg, F. W., Malik, I., O'Reilly, M. A., Hyare, H., Carr, A. S., & Roddie, C. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2024-333924 · Cited by 26
Ho, M., Paruzzo, L., Noll, J. H., Stella, F., Devi, P., Ndeupen, S., Day, Y. A., Chen, G. M., Cohen, I., Ramírez-Fernández, Á., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04121-8 · Cited by 29
Gong, Z., Umoru, G., Monge, J., Shah, N. N., Mohyuddin, G. R., Radhakrishnan, S. V., Chakraborty, R., Rasche, L., Schinke, C., D’Souza, A., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01023-9 · Cited by 22
“In the CARTITUDE 4 study of cilta-cel, 14% of deaths (25/39) among patients who received CAR T-cell infusion ( n = 176) were attributed to causes unrelated to disease progression [5].”
BackgroundElmarasi, M., Elkonaissi, I., Elsabagh, A. A., Elsayed, E., Elsayed, A., Elsayed, B. M. S., Elmakaty, I., & Yassin, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112312 · Cited by 21
Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention
Li, J., Chen, H., Xu, C., Hu, M., Li, J., & Chang, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1422591 · Cited by 25
Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma
Gustine, J. N., Branagan, A. R., Cirstea, D. D., Rexha, F., Han, R., Yee, A. J., Maus, M. V., Frigault, M. J., & Raje, N. S. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025015981 · Cited by 24
New targets and new drugs for hepatobiliary cancers
Chan, S. L., Lamarca, Á., Hsu, C., Moreno, V., Chan, L. L., & Keenan, B. P. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.08.018 · Cited by 28
Petri, K., D’Ippolito, E., Künkele, A., Koehl, U., Busch, D. H., Einsele, H., & Hudecek, M. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01072-4 · Cited by 36
Self-citationLim, K. J. C., Tan, M., Parrondo, R. D., Chhabra, S., Dooley, K. E., Corraes, A. D. M. S., Carabenciov, D. D., Gertz, M. A., hwa, L. Y., Stephens, H. J. B., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01441-3 · Cited by 30
“Pre-treatment predictors for IEC-NP are still, however, yet to be determined.”
Terpos, E., Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Katodritou, E., Hatjiharissi, E., Malandrakis, P., Verrou, E., Golfinopoulos, S., Migkou, M., Manousou, K., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27206 · Cited by 19
“38 However, availability and patient accessibility to CAR T-cell therapy remains a challenge.”
BackgroundHartley-Brown, M. A., Mo, C. C., Nadeem, O., Midha, S., Laubach, J. P., & Richardson, P. G. G. (2024) · Cancers · doi:10.3390/cancers16061166 · Cited by 25
“…the chimeric antigen receptor (CAR) T-cell therapies idecabtagene vicleucel (ide-cel) [22,23] and ciltacabtagene autoleucel (cilta-cel) [24,25]; the bispecific antibodies/T-cell engagers teclistamab [26], talquetamab [27], and elranatamab [28]; and, in Europe, the antibody–drug conjugate…”
BackgroundFu, B., Liu, R., Gao, G., Lin, Z., & He, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1433774 · Cited by 20
Baertsch, M., Schlenzka, J., Hielscher, T., Raab, M. S., Sauer, S., Merz, M., Mai, E. K., Müller‐Tidow, C., Luntz, S. P., Jauch, A. S., et al. (2025) · Blood · doi:10.1182/blood.2024027342 · Cited by 21
Perrot, A., Delimpasi, S., Spanoudakis, E., Frølund, U. C., Belotti, A., Oriol, A., Moreau, P., McFadden, I., Xia, Q., Arora, M., et al. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2322030 · Cited by 20
“…or daratumumab, pomalid-omide, and dexamethasone) had similar ORR and median PFS outcomes (67% and 11.8 months, respectively) to the KPd arm of SELECT, superior outcomes were reported for the chimeric antigen receptor T-cell (CAR-T) cohort (ORR, 85%; median PFS, not reached, respectively) [36].”
ResultInfluentialSelf-citationParkinson‐like neurotoxicity in female patients treated with idecabtagene‐vicleucel
Couturier, A., Escoffre, M., Leh, F., Villoteau, A.-S., Palard, X., Jeune, F. L., Decaux, O., Lamy, T., & Houot, R. (2024) · HemaSphere · doi:10.1002/hem3.131 · Cited by 19
Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
Jin, C., Chen, R., Fu, S., Zhang, M., Teng, Y., Yang, T., Song, F., Feng, J., Hong, R., Cui, J., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010687 · Cited by 26
CAR T cell persistence in cancer
Mueller, K. P., Grenier, J. M., & Weber, E. W. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.08.014 · Cited by 28
van de Donk, N. W. C. J., Moreau, P., Miguel, J. F. S., Mateos, M., Dimopoulos, M. A., Zweegman, S., Gay, F., Engelhardt, M., Mina, R., Zamagni, E., et al. (2025) · HemaSphere · doi:10.1002/hem3.70260 · Cited by 26
Self-citationWu, J. F., & Dhakal, B. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01479-5 · Cited by 21
Self-citationCurrent use of CAR T cells to treat multiple myeloma
Firestone, R., & Mailankody, S. (2023) · Hematology · doi:10.1182/hematology.2023000434 · Cited by 20
Mitigating time toxicity in lymphoma and multiple myeloma
Di, M., Su, C. T., Cowan, A. J., Gopal, A. K., & Banerjee, R. K. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2352086 · Cited by 21
“…data from several randomized trials of cAR-t versus standard anti-MM therapies have demonstrated significant PFS benefits and QOl improvements [4,5,44,45]. while in part due to better disease control, these improved PROs are likely in part due to the decreased time toxicity of cAR-t therapy…”
Updates on CAR T cell therapy in multiple myeloma
Nasiri, F., Asaadi, Y., Mirzadeh, F., Abdolahi, S., Molaei, S., Piri‐Gavgani, S., & Rahbarizadeh, F. (2024) · Biomarker Research · doi:10.1186/s40364-024-00634-5 · Cited by 22
“The results once again confirmed the effectiveness of ide-cel and cilta-cel treatments, with a hazard ratio for PFS of 0.49 for ide-cel [95% CI, 0.38–0.65; P < 0.001], and 0.26 for cilta-cel [95% CI, 0.18–0.38; P < 0.001] [12, 13, 79].”
BackgroundInfluentialBispecific antibodies for the treatment of hematologic malignancies: The magic is T-cell redirection
Shouse, G. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101251 · Cited by 24
Steinhardt, M., Schaefers, C., Leypoldt, L. B., Blau, I., Harzer, M., Zhou, X., Riedhammer, C., Kamili, A., Kosch, R., Topp, L. S., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01330-9 · Cited by 25
Self-citationAntibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma
Tacchetti, P., Talarico, M., Barbato, S., Pantani, L., Mancuso, K., Rizzello, I., Zamagni, E., & Cavo, M. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2344647 · Cited by 19
“Comparable to ide-cel, efficacy of cilta-cel was assessed in earlier lines in the phase 3 CARTITUDE-4 study (NCT04181827) [80], that compared cilta-cel versus standard treatments in 419 patients with RRMM previously treated with 1 to 3 lines of treatment and with lenalidomide-refractory disease.”
MethodResultInfluentialSelf-citationHartley-Brown, M. A., Weisel, K. C., Bitetti, J., Carter, J. A., McNamara, S., Purser, M. F., Palumbo, A., & Richardson, P. G. G. (2024) · British Journal of Haematology · doi:10.1111/bjh.19627 · Cited by 20
Xu, T., Tian, T., Wang, C., Chen, X., Zuo, X., Zhou, H., Bai, J., Zhao, C., Fu, S., Sun, C., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01405-5 · Cited by 21
Gerber, W. K., Xie, Y., & Patel, S. A. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00753 · Cited by 19
Neurotoxicity associated with chimeric antigen receptor T-cell therapy
Wronski, M., Wesselingh, R., Kazzi, C., Seery, N., Ko, K., Li, J. J., Tan, T., Simpson, T., Abbott, C., Fleming, S. A., et al. (2025) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2025.578717 · Cited by 17
Self-citationRole of Immune Cells and Immunotherapy in Multiple Myeloma
Radhakrishnan, V., Golla, U., & Kudva, A. K. (2024) · Life · doi:10.3390/life14040461 · Cited by 20
Capolla, S., Rasool, M., Toffoli, G., & Bo, M. D. (2025) · Cancer Medicine · doi:10.1002/cam4.70726 · Cited by 15
Talquetamab–Daratumumab in Relapsed or Refractory Myeloma
Mina, R., Beksac, M., Rodríguez‐Otero, P., Chen, W., Mateos, M., Li, J., Moreau, P., Cohen, Y. C., Min, C., Jelínek, T., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2604657 · Cited by 28
Self-citationAdoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment
Vu, S. H., Pham, H. H., Pham, T. T. P., Le, T. T., Vo, M.-C., Jung, S., Lee, J., & Nguyen, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1275076 · Cited by 15
“The hematological malignancy still returns to CAR-T-cell-infused patients after 12-13 months, albeit with a high response rate (10, 112).”
BackgroundBridging treatment prior to chimeric antigen receptor T‐cell therapy in multiple myeloma
Bal, S., & Costa, L. J. (2023) · British Journal of Haematology · doi:10.1111/bjh.19227 · Cited by 15
“1,2 In addition to the drug refractoriness of myeloma and the safety profile of a regimen, a personalized approach incorporating patients' existing toxicity burden from prior therapies and comorbidities can also help determine an appropriate bridging strategy.”
BackgroundSelf-citationHadiloo, K., Taremi, S., Safa, S. H., Amidifar, S., & Esmaeilzadeh, A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107158 · Cited by 15
Kfir‐Erenfeld, S., Asherie, N., Lebel, E., Vainstein, V., Assayag, M., Sharon, T. D., Grisariu, S., Avni, B. R., Elias, S., Alexander‐Shani, R., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012967 · Cited by 17
Self-citationPak, W. L. W., Brumwell, N. A., Kabel, C. C., Gutgarts, V., Sathick, I. J., Mailankody, S., Lesokhin, A. M., Landau, H. J., & Shaikh, A. (2024) · Kidney Medicine · doi:10.1016/j.xkme.2024.100856 · Cited by 15
“4,5 However, up to 50% of patients with MM present with decreased kidney function, and some progress to KF despite treat-ment.”
BackgroundZanwar, S., Novak, J. P., Gonsalves, W. I., Howe, M., Braggio, E., Rajkumar, S. V., Binder, M., Jevremović, D., Dasari, S., & Kumar, S. K. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016619 · Cited by 23
Bispecific antibody targets and therapies in multiple myeloma
Rees, M. J., Abdallah, N. H., Yohannan, B., & Gonsalves, W. I. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1424925 · Cited by 19
Blank, L., Pander, G., Mühlberg, E., Mier, W., & Uhl, P. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104524 · Cited by 15
CAR T‐Cell Therapy for Multiple Myeloma: A Clinical Practice‐Oriented Review
Sadek, N. L., Costa, B. A., Nath, K., & Mailankody, S. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3057 · Cited by 16
Barbieri, E., Martino, E. A., Rivolti, E., Quaresima, M., Vigna, E., Neri, A., Morabito, F., & Gentile, M. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2357382 · Cited by 14
“Chimeric antigen receptor T-cell (CAR-T) therapies idecabta-gene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) have recently received FDA approval for the treatment of RRMM on the basis of two phase III trials, KarMMa-3 [112] and CARTITUDE-4 [113], respectively.”
MethodThe Evolving Role of Bridging Therapy during CAR-T Therapy
Bhaskar, S., Dholaria, B., Savani, B. N., & Oluwole, O. O. (2024) · Clinical Hematology International · doi:10.46989/001c.116261 · Cited by 14
Alsdorf, W. H., Diels, J., Ghilotti, F., Mendes, J., Hernando, T., Cost, P., Schecter, J. M., Lendvai, N. K., Patel, N., Triguero, A., et al. (2024) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2024-0080 · Cited by 15
“Details for CARTITUDE-4 have been previously published [7] .”
BackgroundInfluentialSelf-citationUpdates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma
Parekh, D. S., Tiger, Y. K., Jamouss, K. T., Hassani, J., Zerdan, M. B., & Raza, S. (2024) · Cancers · doi:10.3390/cancers16172931 · Cited by 18
Goel, U., Dima, D., Davis, J. A., Ahmed, N., Shaikh, H. G., Lochner, J. S., Abdallah, A.-O. A., Khouri, J., Hashmi, H., & Anwer, F. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14293 · Cited by 16
Pan, D., & Richter, J. R. (2023) · Cancer Management and Research · doi:10.2147/cmar.s372237 · Cited by 18
“Ultimately, the higher response rates with bispecific antibodies over standard regimens must be confirmed through randomized-controlled trials, as has been done with CAR T cells in the KARMMA-3 and CARTITUDE-4 studies.(29,30) The choice between teclistamab and anti-BCMA CAR T is another complex question.”
ResultKelly, K., Cooperrider, J. H., Bishop, M. R., Kosuri, S., Jakubowiak, A. J., & Derman, B. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015721 · Cited by 13
Sequential BCMA CAR T-cell therapy in refractory multiple myeloma
Richardson, T., Holtick, U., Frenking, J. H., Tharmaseelan, H., Balke‐Want, H., Flümann, R., Mai, E. K., Sauer, S., Teipel, R., von Bonin, M., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016712 · Cited by 19
Techaapornkun, P., Rojpalakorn, W., Mejun, N., Khaniya, A., Thammahong, A., Thu, M. S., Hirankarn, N., & Pitakkitnukun, P. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06524-6 · Cited by 19
Next-Generation Therapies for Multiple Myeloma
Meermeier, E. W., Bergsagel, P. L., & Chesi, M. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-014236 · Cited by 12
Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma
Miller, K. C., Hashmi, H., & Rajeeve, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1398902 · Cited by 24
“More recently, the emergence of immunotherapies including chimeric antigen receptor (CAR) T cell therapy further expanded the myeloma treatment armamentarium (1 – 7).”
BackgroundBeyond BCMA: newer immune targets in myeloma
Tan, M. S. Y., Chen, Y., & Smith, E. L. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023010856 · Cited by 15
Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma
Korst, C. L. B. M., O’Neill, C. A., Bruins, W. S. C., Cosovic, M., Twickler, I., Verkleij, C. P. M., Clerre, D. L., Themeli, M., Chion-Sotinel, I., Zweegman, S., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008769 · Cited by 22
Self-citationZugasti, I., Tormo-Ratera, M., Oliver‐Caldés, A., Soler-Perromat, J. C., González‐Calle, V., Moreno, D. F., Cabañas, V., López‐Muñoz, N., Bartolomé-Solanas, Á., Español‐Rego, M., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024014360 · Cited by 15
Self-citationMechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma
Yue, T., Sun, Y., Dai, Y., & Jin, F. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101256 · Cited by 19
Merz, M., Gagelmann, N., Smaili, S., Flossdorf, S., Sauer, S., Scheid, C., von Tresckow, B., Wulf, G. G., Weisel, K. C., Blau, I. W., et al. (2025) · Blood · doi:10.1182/blood.2025028330 · Cited by 19
Self-citationBoosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens
Rieger, L., Irlinger, K., Füchsl, F., Tietje, M. R., Purcarea, A., Barbian, N., Faber, M., Vogelsang, C., Pfeuffer, L., Stotz, S., et al. (2025) · Blood · doi:10.1182/blood.2024027616 · Cited by 18
Self-citationBCMA CAR-T cells in multiple myeloma–ready for take-off?
Scheller, L., Tebuka, E., Rambau, P., Einsele, H., Hudecek, M., Prommersberger, S., & Danhof, S. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2276676 · Cited by 16
“%) are at least partly attributed to more advanced disease stages in the KarMMa 3 trial, with a significant higher percentage of triple class refractory patients (65% KarMMa-3 vs. 14.4% cARtitUDe-4) [33,36].”
BackgroundInfluentialSelf-citationBesliu, C., Tănase, A., Rotaru, I., Espinoza, J., Vidal, L., Poelman, M., Juan, M., de Larrea, C. F., & Saini, K. S. (2025) · Cancers · doi:10.3390/cancers17030525 · Cited by 17
“…lenalidomide-refractory disease, the ≥ CR rate was 73.1% with CAR T cell therapy ciltacabtagene autoleucel (Cilta-cel) in the CARTITUDE-4 trial [28] and 39.4% in patients with RRMM and multiple prior lines of therapy treated with the T cell engager bispecific antibody teclistamab in the…”
InfluentialSelf-citationFortuna, G. G., Peres, L. C., Назаренко, Е. Б., Corraes, A. D. M. S., Hovanky, V. N., Shune, L. O., McGuirk, J. P., Avilla, G. D., Khouri, J., Dima, D., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016966 · Cited by 13
“Although cilta-cel and ide-cel are associated with exceptional outcomes in MM when compared with previously introduced novel agents, 12,13 multiple real-world studies have suggested improved outcomes with cilta-cel when compared with ide-cel in patients with RRMM. 30,31 For instance, in a…”
Self-citationT-cell exhaustion in multiple myeloma
Żyłka, K., Kubicki, T., Gil, L., & Dytfeld, D. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2370552 · Cited by 16
“[125].”
Self-citationChimeric antigen receptor-T-cell therapies going viral: latent and incidental viral infections
Kampouri, E., Reynolds, G. K., Teh, B. W., & Hill, J. A. (2024) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000001066 · Cited by 11
Targeting BCMA in multiple myeloma: designs, challenges, and future directions
Hu, Y., Xie, Y., Wang, X., Yang, L., Geng, H., Yi, Z., Zhang, Y., Ma, L., & Chen, F. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03913-0 · Cited by 14
CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?
Fischer, L., Grieb, N., Platzbecker, U., Vučinić, V., & Merz, M. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14051 · Cited by 15
CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma
Dima, D., Banerjee, R., & Hansen, D. K. (2025) · Hematology · doi:10.1182/hematology.2025000721 · Cited by 13
van de Donk, N. W. C. J., Sonneveld, P., & Einsele, H. (2026) · Blood · doi:10.1182/blood.2025032536 · Cited by 15
Self-citationCiltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial
Nadeem, O., dos Santos, D. M. C., Nikiforow, S., Bosch‐Vilaseca, A., O’Donnell, E., Redd, R. A., DeBraganca, K., Sperling, A. S., Liu, Y., McEntire, C. R. S., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04365-y · Cited by 17
“The efficacy of cilta-cel in this HR-SMM cohort also appears greater than that typically observed in RRMM cohorts, including patients treated earlier in relapse (for example, CARTITUDE-4) 1,3 , supporting the hypothesis that immune fitness and disease biology at earlier stages may improve outcomes.”
Self-citationMo, C. C., Richardson, E., Calabretta, E., Corrado, F., Kocoglu, M. H., Baron, R. M., Connors, J. M., Iacobelli, M., Wei, L. J., Rapoport, A. P., et al. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101218 · Cited by 10
Metadata
- Authors
- San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., Leleu, X., Avivi, I., Cavo, M., Ishida, T., Kim, S. J., Roeloffzen, W., van de Donk, N. W. C. J., Dytfeld, D., Sidana, S., Costa, L. J., Oriol, A., Popat, R., Khan, A. M., Cohen, Y. C., Ho, P. J., Griffin, J., Lendvai, N., Lonardi, C., Slaughter, A., Schecter, J. M., Jackson, C. C., Connors, K., Li, K., Zudaire, E., Chen, D., Gilbert, J., Yeh, T.-M., Nagle, S., Florendo, E., Pacaud, L., Patel, N., Harrison, S. J., & Einsele, H.
- Affiliations
- From the Cancer Center Clínica Universidad de Navarra, Centro Investigación Medica Aplicada, Instituto de Investigación de Navarra, Centro Investigación Biomédica en Red Cáncer (CIBERONC), Pamplona (J.S.-M.), the University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro Investigación del Cáncer, CIBERONC, Salamanca (M.-V.M.), the Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona (C.F.L.), the Hematological Malignancies Clinical Research Unit, Hospital 12 de Octubre Universidad Complutense, Centro Nacional de Investigaciones Oncológicas, CIBERONC, Madrid (J.M.-L.), and the Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.) — all in Spain; the Medical College of Wisconsin, Milwaukee (B.D.); the University College London Cancer Institute (K.Y.) and University College London Hospitals, NHS Foundat...
- Medical College of Wisconsin (US)
- Inserm (FR)
- University Medical Center Groningen (NL)
- Poznan University of Medical Sciences (PL)
- University College London Hospitals NHS Foundation Trust (GB)
- The University of Sydney (AU)
- The Royal Melbourne Hospital (AU)
- ORCID
- Dhakal, Binod
- Yong, Kwee
- Spencer, Andrew
- Anguille, Sébastien
- Mateos, María-Victoria
- Moreau, Philippe
- Touzeau, Cyrille
- Leleu, Xavier
- Avivi, Irit
- Ishida, Tadao
- Kim, Seok Jin
- Roeloffzen, Wilfried
- Dytfeld, Dominik
- Sidana, Surbhi
- Costa, Luciano J.
- Oriol, Albert
- Popat, Rakesh
- Khan, Abdullah M.
- Ho, P. Joy
- Lendvai, Nikoletta
- Schecter, Jordan M.
- Jackson, Carolyn C.
- Li, Katherine
- Chen, Diana
- Nagle, Sarah
- Pacaud, Lida
- Patel, Nitin
- Harrison, Simon J.
- Einsele, Hermann
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-07-27
- Volume
- 389
- Issue
- 4
- Pages
- 335-347
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4379375986
- Semantic Scholar
- e537b398daa738a9f57ecb0da894878f49df8dae
- Cited by
- 827
- References
- 27
- Citations by year
- 2026: 257 · 2025: 279 · 2024: 230 · 2023: 60
- FWCI
- 169.95
- Type
- journal article
- Language
- en
- Open access
- green
- research.rug.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Funders
- Janssen Research & Development, LLC
- Legend Biotech USA Inc.
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- cilta-cel, ciltacabtagene autoleucel, lenalidomide-refractory multiple myeloma, progression-free survival, standard of care comparison, cytokine release syndrome, neurotoxicity, non-relapse mortality, minimal residual disease, relapsed/refractory multiple myeloma, adverse events
- MeSH terms
- Antineoplastic Agents, Immunological, Lenalidomide, Progression-Free Survival, Humans, Multiple Myeloma, Immunotherapy, Adoptive, Drug Resistance, Neoplasm, Neurotoxicity Syndromes, B-Cell Maturation Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.